A single institution experience with palbociclib toxicity requiring dose modifications

PURPOSE: Since the widespread implementation of adding palbociclib to endocrine therapy in clinical practice, myelosuppression is becoming increasingly recognized as a toxicity that may lead to dose modification. We aimed to characterize toxicities observed with palbociclib resulting in dose modific...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Cho, May, Yu, Kim Wai, Waisman, James, Yuan, Yuan, Mortimer, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838140/
https://www.ncbi.nlm.nih.gov/pubmed/29218462
http://dx.doi.org/10.1007/s10549-017-4606-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838140/
https://www.ncbi.nlm.nih.gov/pubmed/29218462
http://dx.doi.org/10.1007/s10549-017-4606-9

Ejemplares similares